-
Signature
-
/s/Steven Adams, Attorney-in-Fact
-
Stock symbol
-
ATNXQ
-
Transactions as of
-
Jul 15, 2022
-
Transactions value $
-
$500
-
Form type
-
4
-
Date filed
-
7/18/2022, 04:19 PM
Transactions Table
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
transaction |
ATNXQ |
Common Stock |
Award |
$500 |
+843 |
+11.56% |
$0.59 |
8.13K |
Jul 15, 2022 |
Direct |
F1 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
holding |
ATNXQ |
Stock Option (Right to Buy) |
|
|
|
|
|
70K |
Jul 15, 2022 |
Common Stock |
70K |
$17.29 |
Direct |
F2 |
holding |
ATNXQ |
Stock Option (Right to Buy) |
|
|
|
|
|
30K |
Jul 15, 2022 |
Common Stock |
30K |
$10.26 |
Direct |
F3 |
holding |
ATNXQ |
Stock Option (Right to Buy) |
|
|
|
|
|
9K |
Jul 15, 2022 |
Common Stock |
9K |
$3.56 |
Direct |
F4 |
holding |
ATNXQ |
Restricted Stock Units |
|
|
|
|
|
9K |
Jul 15, 2022 |
Common Stock |
9K |
|
Direct |
F5, F6 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
Remarks:
Chief Business and Commercial Officer, Proprietary Drugs